1-5 of 5
Dorothy Romanus, RPh, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)

Larysa Sanchez, MD, Dasha Cherepanov, Dorothy Romanus, RPh, PhD, Aditya Raju, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-136597
Published: 2020
Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1827.
https://doi.org/10.1182/blood-2019-121658
Published: 2019
Journal Articles

Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.)

Sikander Ailawadhi, MD, Dorothy Romanus, RPh, PhD, Dasha Cherepanov, PhD, Yu Yin, MS, MA, Meng-Ru Cheng, MSPH, Parameswaran Hari, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3164.
https://doi.org/10.1182/blood-2019-124301
Published: 2019
Journal Articles

Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study

Saad Z. Usmani, MD, Vania T. M. Hungria, MD PhD, Xavier Leleu, MD PhD, Hans C. Lee, MD, Faith E. Davies, MD, Caitlin L. Costello, MD, Robert M Rifkin, MD, Katja Weisel, MD, Ajai Chari, MD, Noemi Puig, MD PhD, Mario Boccadoro, MD, Gordon Cook, Jesus G. Berdeja, MD, Jeffrey A Zonder, MD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Jorge Vela-Ojeda, MD PhD, Roman Hajek, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jim Omel, MD, Brittany Demers, BS, BA, Dorothy Romanus, RPh, PhD, Kaili Ren, PhD, Tomas Skacel, MD PhD, Dawn Marie Stull, Pharm.D., BCOP, Evangelos Terpos, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3289.
https://doi.org/10.1182/blood-2018-99-112846
Published: 2018
Journal Articles

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Christopher R. Cogle, MD, Sudipto Mukherjee, MD MPH, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Rita Percy, Michael E. Petrone, MD MPH, Scott Megaffin, Ayanna M Anene, BS, Jesse Ortendahl, MS, Dorothy Romanus, RPh, PhD, Tanya GK Bentley, PhD
Journal: Blood
Blood (2014) 124 (21): 1928.
https://doi.org/10.1182/blood.V124.21.1928.1928
Published: 2014